Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients-Reference-Cited by-同舟云学术

Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients

Published:2012-08-01 Issue:12 Volume:87 Page:1047-1051
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Scappini Barbara,Gianfaldoni Giacomo,Caracciolo Francesco,Mannelli Francesco,Biagiotti Caterina,Romani Claudio,Pogliani Enrico M.,Simonetti Federico,Borin Lorenza,Fanci Rosa,Cutini Ilaria,Longo Giovanni,Susini Maria Chiara,Angelucci Emanuele,Bosi Alberto

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.23308/fullpdf

Reference25 articles.

1. Acute myeloid leukemia in adults: Where do we go from here?;Schiffer;Cancer Chemother Pharmacol,2001

2. Synthesis and biologic activity of 2′-fluoro-2-halo derivatives of 9-β-D-arabinofuranosyladenine;Montgomery;J Med Chem,1992

3. Antitumor activity of 2-fluoro-2′-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase;Parker;Cancer Gene Ther,2003

4. Oral antilymphocyte activity and induction of apoptosis bu 2-chloro-2′.arabino-fluoro-2′deoxyadenosine;Carson;Proc Natl Acad Sci USA,1992

5. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers;Kantarjian;J Clin Oncol,2003

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DFT Calculation, ADME/T and Molecular Docking Approach of Methyl 2-oxo-1,2-dihydrofuro[3,4-d] pyrimidine-3(4H)carboxylate;Journal of the Mexican Chemical Society;2024-06-19

2. Non-Immunotherapy Approaches for Relapsed or Refractory AML: An Update for 2024;Acta Haematologica;2023-10-31

3. Novel N-benzyl-2-oxo-1,2-dihydrofuro [3,4-d]pyrimidine-3(4H)-carboxamide as anticancer agent: Synthesis, drug-likeness, ADMET profile, DFT and molecular modelling against EGFR target;Heliyon;2023-01

4. Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy;Nature Chemical Biology;2021-03-04

5. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial;Transplantation and Cellular Therapy;2021-02